JP2015189716A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015189716A5 JP2015189716A5 JP2014068897A JP2014068897A JP2015189716A5 JP 2015189716 A5 JP2015189716 A5 JP 2015189716A5 JP 2014068897 A JP2014068897 A JP 2014068897A JP 2014068897 A JP2014068897 A JP 2014068897A JP 2015189716 A5 JP2015189716 A5 JP 2015189716A5
- Authority
- JP
- Japan
- Prior art keywords
- hyaluronic acid
- acid synthesis
- casein
- synthesis promoter
- degradation product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000015572 biosynthetic process Effects 0.000 claims description 13
- 229920002674 hyaluronan Polymers 0.000 claims description 13
- 229960003160 hyaluronic acid Drugs 0.000 claims description 13
- MAKUBRYLFHZREJ-JWBQXVCJSA-M sodium;(2S,3S,4R,5R,6R)-3-[(2S,3R,5S,6R)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate Chemical compound [Na+].CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@H](O)[C@H]1O MAKUBRYLFHZREJ-JWBQXVCJSA-M 0.000 claims description 13
- 238000003786 synthesis reaction Methods 0.000 claims description 13
- 230000002194 synthesizing Effects 0.000 claims description 13
- 239000005018 casein Substances 0.000 claims description 7
- 235000021240 caseins Nutrition 0.000 claims description 7
- 230000001737 promoting Effects 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- 239000000546 pharmaceutic aid Substances 0.000 claims description 2
- 239000007857 degradation product Substances 0.000 claims 3
- 241000283690 Bos taurus Species 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 description 2
- 231100000592 few side effect Toxicity 0.000 description 2
- 239000002253 acid Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
Description
本発明は、副作用が少なく、安全性に優れたヒアルロン酸合成促進剤、当該ヒアルロン酸合成促進剤を含む医薬、及びヒアルロン酸合成促進用食品組成物を提供することにある。 An object of the present invention is to provide a hyaluronic acid synthesis promoter having few side effects and excellent safety, a medicament containing the hyaluronic acid synthesis promoter, and a food composition for promoting hyaluronic acid synthesis .
すなわち、本発明は、カゼイン分解物を有効成分とするヒアルロン酸合成促進剤、当該ヒアルロン酸促進剤及び薬学的に許容される賦形剤を含む医薬、及びカゼイン分解物を有効成分とするヒアルロン酸合成促進用食品組成物を提供するものである。 That is, the present invention is hyaluronic acid synthesis promoting agent comprising as an active ingredient casein hydrolyzate, medicaments comprising those said hyaluronic acid promoter and a pharmaceutically acceptable excipient, and hyaluronic that casein hydrolyzate as an active ingredient A food composition for promoting acid synthesis is provided.
本発明は、副作用が少なく、安全性に優れたヒアルロン酸合成促進剤、当該ヒアルロン酸合成促進剤を含む医薬、及びヒアルロン酸合成促進用食品組成物を提供することができる。 INDUSTRIAL APPLICABILITY The present invention can provide a hyaluronic acid synthesis promoter having few side effects and excellent safety, a pharmaceutical containing the hyaluronic acid synthesis promoter, and a food composition for promoting hyaluronic acid synthesis .
Claims (5)
アルロン酸合成促進剤。 The hyaluronic acid synthesis promoter according to claim 1 or 2, wherein the casein degradation product has a molecular weight of 1000 daltons or less.
賦形剤を含む医薬。 The pharmaceutical containing the hyaluronic acid synthesis promoter as described in any one of Claims 1-3, and a pharmaceutically acceptable excipient | filler.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014068897A JP6243777B2 (en) | 2014-03-28 | 2014-03-28 | Hyaluronic acid synthesis accelerator |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014068897A JP6243777B2 (en) | 2014-03-28 | 2014-03-28 | Hyaluronic acid synthesis accelerator |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015189716A JP2015189716A (en) | 2015-11-02 |
| JP2015189716A5 true JP2015189716A5 (en) | 2016-08-18 |
| JP6243777B2 JP6243777B2 (en) | 2017-12-06 |
Family
ID=54424540
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014068897A Active JP6243777B2 (en) | 2014-03-28 | 2014-03-28 | Hyaluronic acid synthesis accelerator |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP6243777B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7273996B2 (en) | 2019-12-20 | 2023-05-15 | 株式会社日立ハイテク | Molecular weight marker for electrophoresis, nucleic acid fractionation method, and nucleic acid size analysis method |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0773507B2 (en) * | 1988-11-19 | 1995-08-09 | 森永乳業株式会社 | Low molecular weight peptide composition and method for producing the same |
| EP1359157A1 (en) * | 2002-04-29 | 2003-11-05 | Société des Produits Nestlé S.A. | Metallo-proteinase inhibitory agent |
| US20100167979A1 (en) * | 2006-02-09 | 2010-07-01 | Calpis Co. Ltd | Rheumatoid arthritis-preventive agent for oral intake |
| CN101695382A (en) * | 2009-10-30 | 2010-04-21 | 洛阳新春都生物制药有限公司 | Calcium supplementing preparation with functions of improving bones and joints |
| CN103446577B (en) * | 2013-09-03 | 2016-03-30 | 庞会心 | A kind of arthritic pharmaceutical composition of prevention and therapy and application thereof |
-
2014
- 2014-03-28 JP JP2014068897A patent/JP6243777B2/en active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7273996B2 (en) | 2019-12-20 | 2023-05-15 | 株式会社日立ハイテク | Molecular weight marker for electrophoresis, nucleic acid fractionation method, and nucleic acid size analysis method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017004592A (en) | Pharmaceutical formulations for the oral delivery of peptide or protein drugs. | |
| WO2016131067A3 (en) | Pharmaceutical compositions comprising meloxicam | |
| WO2016064082A3 (en) | Novel aminoalkyl benzothiazepine derivative and use thereof | |
| FI3562486T3 (en) | Use of sublingual dexmedetomidine for the treatment of agitation | |
| AR090491A1 (en) | TREATMENT OF MULTIPLE SCLEROSIS WITH A COMBINATION OF LAQUINIMOD AND DIMETILO FUMARATE | |
| WO2015160975A3 (en) | Combination of a pi3k inhibitor with a bcl-2 inhibitor for use in the treatment of cancer | |
| MX362838B (en) | Extended release, abuse deterrent pharmaceutical compositions. | |
| WO2017022962A8 (en) | Composition for preventing or treating immune disease, comprising ripk inhibitor as active ingredient | |
| MX2021008432A (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders. | |
| EA201991287A1 (en) | SOLID PHARMACEUTICAL COMPOSITIONS BASED ON TIKAGRELOR FOR ORAL USE | |
| MX2017003928A (en) | Long acting pharmaceutical compositions. | |
| TR201713929A2 (en) | Hemostatic compositions of chitosan and alginate | |
| WO2014033526A9 (en) | Pharmaceutical compositions of etoricoxib | |
| WO2016112875A3 (en) | Diphenyl derivative and uses thereof | |
| JP2020536085A5 (en) | ||
| WO2020127819A3 (en) | Pharmaceutical composition comprising apixaban | |
| MX363389B (en) | Pharmaceutical composition comprising amorphous ivabradine. | |
| BR112018010052A2 (en) | peptides with antiangiogenic, anti-lymphogenic and antiedemic properties and nanoparticle formulations | |
| MX2022006940A (en) | Pharmaceutical compositions comprising cabotegravir. | |
| PH12018500817A1 (en) | Pharmaceutical composition comprising metformin and lobeglitazone | |
| MX2017014776A (en) | Pharmaceutical combination of everolimus with dactolisib. | |
| WO2015082590A3 (en) | Bis-mmf derivatives | |
| WO2015001541A3 (en) | Pharmaceutical film composition | |
| EA201991265A1 (en) | MEDICINAL FORMS WITH DELAYED DELIVERY CONTAINING DIMETHYLFUMARATE | |
| JP2015189716A5 (en) |